Welcome to our dedicated page for ProQR Therapeutics N.V. SEC filings (Ticker: PRQR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProQR Therapeutics N.V. filings document a Nasdaq-listed foreign private issuer furnishing Form 6-K current reports for its RNA therapeutics business. The disclosures describe the Axiomer RNA editing platform, ADAR-mediated oligonucleotide design, pipeline programs including AX-0810, AX-2402 and AX-2911, scientific presentations, collaborations, and annual operating and financial results.
The filing record also covers governance and capital-market matters, including annual general meeting notices, agenda materials, proxy forms, proposed articles-of-association amendments, board nominations and board-composition updates. Several Form 6-K reports incorporate company materials by reference into Form F-3 registration statements, linking current business updates with registered securities disclosure.
ProQR Therapeutics N.V. has scheduled a virtual Investor and Analyst Event for April 8, 2026, titled “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810.” The event will highlight its broader RNA editing pipeline, introduce new programs with upcoming clinical data, and unveil the primary indication for lead candidate AX-0810.
The company reiterates its focus on its proprietary Axiomer™ RNA base editing platform, which uses the body’s own ADAR enzymes to make single-nucleotide edits in RNA that may correct disease-causing mutations or modulate protein expression. ProQR also reminds readers of anticipated target engagement data for AX-0810 in the first half of 2026 and additional clinical updates across multiple programs during 2026.
ProQR Therapeutics N.V. director Valerio Domenico filed an initial ownership report showing his equity position in the company. He directly holds 420,729 Ordinary Shares and has additional indirect exposure through a Valerio family foundation, for which he disclaims beneficial ownership except for any pecuniary interest.
He also holds multiple employee share options over Ordinary Shares with exercise prices ranging from $1.98 to $15.78 per share and expiration dates between 2026 and 2035. These options give him rights to buy additional shares over time as they vest, aligning part of his compensation with ProQR’s long-term share performance.
ProQR Therapeutics N.V. director and Chief Scientific Officer Gerardus Johannes Platenburg has filed an initial statement of beneficial ownership. The filing lists direct holdings of 824,388 Ordinary Shares.
It also details multiple option grants to buy Ordinary Shares at exercise prices ranging from $0.6700 to $15.7800, with expiration dates between 2026-12-31 and 2035-12-31. Footnotes explain that some options are fully vested, while others vest 25% on specific January 1 dates from 2024 through 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to his continuous service.
The transaction summary shows holding entries only, with no reported purchases, sales, exercises, gifts, or tax-withholding dispositions in this filing.
ProQR Therapeutics N.V. director Martin Alexander Maier reported his holdings of share options that give him the right to buy Ordinary Shares at fixed prices. The filing lists several option grants with exercise prices between $1.02 and $3.41 per share and expirations from 2032 through 2035.
The derivative positions include options over 500 Ordinary Shares at an exercise price of $1.02 expiring on February 29, 2032, and additional options over 500 shares at $3.41 and 500 shares at $1.98. Larger grants cover 14,186 shares at $1.90, 22,128 shares at $2.65, and 25,192 shares at $2.02, with staggered expiration dates. Footnotes explain that some options are fully vested, while others vest 25% on specified dates such as January 1, 2024, January 1, 2025, May 22, 2025, January 1, 2026, and January 1, 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to his continuous service.
ProQR Therapeutics N.V. director Alison Frances Lawton filed an initial ownership report listing multiple share option awards over Ordinary Shares. These options have exercise prices ranging from 1.9800 to 15.7800 and expiration dates between 2026 and 2035, all held directly.
Footnotes explain that some options are fully vested, while others vest over time. For several grants, 25% of the shares vest on January 1 of 2024, 2025, 2026, or 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service to the company.
ProQR Therapeutics N.V. Chief Financial Officer Dennis Hom filed an initial ownership report showing holdings of share options over Ordinary Shares. He reports options covering 750,000 shares at an exercise price of $1.66 expiring on April 30, 2035 and options over 250,000 shares at $2.02 expiring on December 31, 2035, with vesting beginning in 2026 and 2027 and continuing in quarterly installments, subject to his continued service.
ProQR Therapeutics N.V. director Theresa Heggie filed an initial ownership report showing option-based and share holdings in the company. She directly holds several "Share Option (Right to Buy)" awards on Ordinary Shares, including 100,000 underlying shares at an exercise price of $6.73 expiring on October 31, 2033, alongside other options with exercise prices ranging from $0.67 to $9.91 and expirations through 2035. She also directly holds 43,623 Ordinary Shares. Footnotes state that one option grant is fully vested and others vest 25% on specified dates with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service.
ProQR Therapeutics N.V. director Bart Filius filed an initial ownership report detailing his stock option holdings. The Form 3 lists multiple options to purchase ordinary shares at fixed exercise prices, with expiration dates ranging from 2029 through 2035.
One option grant is noted as fully vested, while others vest 25% on specific January 1 dates from 2024 through 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to his continued service. The filing reports holdings only and does not show any recent share purchases or sales.
ProQR Therapeutics N.V. Chief Executive Officer Daniel Anton de Boer has filed an initial ownership report listing a series of share options over Ordinary Shares. These options carry exercise prices between $0.66 and $15.78 per share, with expirations from 2026 through 2035. The filing shows existing option holdings only, with no open-market purchases or sales reported.
ProQR Therapeutics N.V. director Begona Carreno-Gomez has reported existing holdings of five share option awards over Ordinary Shares. These options carry exercise prices of $0.95, $1.98, $2.02, $2.65 and $3.41 per share, with underlying amounts of 3,565, 23,489, 25,192, 22,128 and 22,903 Ordinary Shares and expirations between October 31, 2032 and December 31, 2035. For each grant, 25% of the shares vest on specified dates from November 1, 2023 through January 1, 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service.